Transforming Revision Surgery.

At Amotio, we are addressing a significant unmet need in orthopaedic revision surgery. Our patient-matched technology is designed to make bone cement removal safer, more precise, and more efficient, helping surgeons tackle one of the most technically demanding steps in revision total hip arthroplasty.

Revision joint replacement is a large and growing global market, driven by increasing primary procedure volumes, ageing implant populations, and the rising complexity of revision cases. Amotio’s solution combines advanced imaging, personalised surgical planning, and precision engineered instrumentation to improve surgical accuracy, procedural efficiency, and consistency in cement removal.

Recognition in this list reflects the strength of our technology, the expertise of our team, and the support of our clinical collaborators, investors, and strategic partners. It also highlights Wales’ emergence as a centre for world-class medical device innovation with global commercial potential.

As we advance toward first-in-human clinical studies and future regulatory milestones, we remain focused on building a scalable platform capable of improving outcomes for surgeons, healthcare systems, and patients worldwide.

We would like to thank Healthcare Digital for this recognition and extend our congratulations to the other outstanding companies featured.

Read more at 20 Future Welsh HealthTech and MedTech Leaders

Amotio is pleased to announce that we will be attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting this March in New Orleans.

A central focus of our visit will be to connect with arthroplasty and revision surgeons, particularly those working with cemented techniques in complex joint reconstruction. Amotio is developing a patient-specific solution designed to address the ongoing challenge of safe, accurate and efficient removal of bone cement during revision surgery. We are keen to discuss current clinical workflows, unmet needs, and how personalised planning and instrumentation may support improved surgical precision, efficiency and confidence for the operating team.

Alongside clinical engagement, AAOS provides an important opportunity for Amotio to meet with experienced sales agents and distributor partners operating within the US orthopaedic market. As an early-stage company preparing for international expansion, we are seeking aligned commercial partners who share our focus on clinical value, quality systems and responsible market development.

Attending AAOS marks a defining moment for Amotio. From our foundations in the Netherlands and Wales, UK , this first step onto the US stage reflects both the strength of our progress and our ambition to contribute meaningful innovation to revision arthroplasty on a global scale. If you are attending AAOS in March and would like to meet with the Amotio team, whether as a surgeon, clinical leader or commercial partner, we would welcome the opportunity to connect and continue the conversation.

You can find the Amotio team at Booth 746

Amotio has achieved ISO 13485 certification, formally recognising the quality management system that underpins how we design, develop, and operate as a medical device company.

Quality at Amotio is embedded across the entire organisation and reflected in every design decision, process, and interaction. Through this accreditation, we reaffirm our commitment to the standards and foundations upon which the company is built, strengthening our responsibility to patients, clinicians, and healthcare systems.

This achievement also serves as a foundation for continuous improvement, ensuring that our practices evolve to meet the highest levels of safety, reliability, and performance.